Status:
COMPLETED
Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects
Lead Sponsor:
LEO Pharma
Conditions:
Psoriasis Vulgaris
Eligibility:
MALE
20-40 years
Phase:
PHASE1
Brief Summary
This trial is looking at whether the LEO 90100 foam causes irritation of the skin in healthy Japanese male adults without psoriasis. A single application of LEO 90100 foam and its vehicle will each be...
Eligibility Criteria
Inclusion
- Key
- Signed informed consent has been obtained.
- Healthy Japanese male subjects.
- Aged 20 to 40 years inclusive.
- Key
Exclusion
- Body Mass Index outside the range 18-25 kg/m²
- Use of any medication (systemic or topical) within 2 weeks of Day 1.
Key Trial Info
Start Date :
January 30 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 20 2018
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03442244
Start Date
January 30 2018
End Date
February 20 2018
Last Update
February 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Co. LTA HAKATA clinic
Fukuoka, Japan